Table 3 HLA-G and -F isoform distribution in patients with and without a pathological complete response (pCR).

From: HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment

Biomarker

No pCR (n = 70)

pCR (n = 45)

P value

HLA-F1

0.27 (0.15, 0.56)

0.26 (0.15, 0.41)

0.60

HLA-F3

0.50 (0.13, 2.61)

0.86 (0.14, 2.22)

0.78

HLA-G1

2.72 (1.68, 6.35)

2.90 (1.36, 6.37)

0.85

HLA-G2

0.00 (0.00, 0.00)

0.00 (0.00, 0.00)

0.60

HLA-G3

2.16 (0.86, 4.25)

2.42 (0.86, 4.34)

0.81

HLA-G5

1.35 (0.50, 4.92)

1.86 (0.35, 4.15)

0.77

HLA-G6

0.16 (0.08, 0.45)

0.20 (0.10, 0.44)

0.64

  1. Protein bands from Western blots were quantified using ImageJ. GAPDH was used as an internal protein control, and placental tissue was used as a reference sample for each blot. The isoform expression pattern was determined semiquantitatively by normalizing to GAPDH relative to the reference sample (HLA isoform/GAPDH ratio). The median and interquartile range (25th percentile, 75th percentile) of the HLA isoform/GAPDH ratio were calculated for pCR and no pCR, and P values were calculated using the Wilcoxon rank sum test.
  2. HLA human leukocyte antigen, pCR pathological complete response.
Back to article page